Loading...
Treatment of infections caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa presents a significant clinical challenge. Owing to a paucity of available drugs and limitations in regulatory approval processes in guidance on optimal therapy for these type of infections, clinicians have only in vitro studies and case reports to inform treatment of these infections. Now, researchers present an in vitro analysis of ceftolozane-tazobactam (CT) and meropenem (MER) against XDR P. aeruginosa (MER minimum inhibitory concentration [MIC], 8 mg/L; CT MIC, 2/4 mg/L). They used a 14-day hollow-fiber infection model that simulated clinical exposure to the two drugs (CT 2 g/1 g every 8 hours, MER 2 g every 8 hours), alone and in combination, and…